Viral Therapy For Skeletal Muscle Alpha-actin Disease And Discovery Of Novel Neuromuscular Disease Genes And Mechanisms
Funder
National Health and Medical Research Council
Funding Amount
$324,028.00
Summary
This research project is the next logical step towards treating patients with skeletal muscle actin disease - using viral delivery of normal actin genes in animal models of actin disease. Another arm of this project is to investigate the genetics and mechanisms causing two very different groups of muscle disorders in the Australian population: devastating muscle weakness in the foetal akinesias and enhanced muscle strength and bulk in individuals with strongman syndromes.
Novel Gene Identification And Characterisation In Epilepsy.
Funder
National Health and Medical Research Council
Funding Amount
$303,964.00
Summary
Epilepsy is a serious neurological disorder affecting up to 5% of the population at some point in their lives. Approximately 70% cases of epilepsy are genetic, but very few of the genes involved have been identified. This project will use state-of-the-art techniques to identify genetic mutations causing an inherited form epilepsy affecting infants. This research is expected to reveal new gene families involved in the genesis of epilepsy and thus new targets for the development of treatments.
Disease Gene Discovery And Improved Genetic Diagnosis In Neuromuscular Disorders
Funder
National Health and Medical Research Council
Funding Amount
$473,321.00
Summary
Paediatric nerve and muscle disorders result in weakness, chronic disability and often early death. Over half of all affected children do not yet have a genetic diagnosis. This project will use advanced sequencing technology to increase genetic diagnosis rates and identify new disease-causing genes. This will result in improved patient care and a better understanding of the biological pathways altered by these disorders. It will also facilitate the identification of targets for future therapies.
Unravelling The Molecular Basis Of Amyotrophic Lateral Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$342,325.00
Summary
The only known causes of ALS are gene mutations. State-of-the-art technologies will be used to find genetic causes of ALS to add to existing diagnostic testing and facilitate investigation into disease mechanism. ALS patients experience different disease courses, with variable age of onset, progression and duration of disease even among those with identical gene mutations. We will examine a well-characterised ALS patient cohort with differing disease manifestations to identify disease modifiers.
A Zebrafish Model Of Facioscapulohumeral Dystrophy For Therapy Development And Functional Studies
Funder
National Health and Medical Research Council
Funding Amount
$390,601.00
Summary
This project seeks to develop a zebrafish model for a genetic muscle-wasting disease called facioscapulohumeral dystrophy (FSHD). Our zebrafish model will enable us to better understand the biological mechanisms underlying the disease, as well as provide a platform for therapeutic testing and discovery.
Development And Application Of Novel Bioinformatics Approaches To Identify Pathogenetic Mechanisms Underlying Migraine
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Migraine is a public health problem. Although GWAS lead to robust findings, the mechanisms and therapeutic strategies are unknown. This is caused by limited sample size hampering obtaining large number of SNPs by GWAS. Integrating priori knowledge with bioinformatics studies is promising to discover hidden SNPs. Here, I will develop a novel approach to find novel genetic risk loci and genes by integrating comprehensive knowledge on SNPs and genes with GWAS instead of increasing sample.
Defining FMR1 And SNRPN Epigenetic Signatures Associated With Neurodevelopmental Disorders
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Fragile X Syndrome and imprinting disorders such as Prader-Willi Syndrome and Angelman Syndrome are characterised by variable penetrance for intellectual disability, motor delay and autism spectrum disorder. This project aims to investigate the prognostic value of using blood-based biomarker tests and sensitive neuroscience informed measures to predict risk and severity of neuropsychological problems in children affected by these disorders.